Cytokeratin 8 Antibody (Ks8.7): sc-101459

Cytokeratin 8 Antibody (Ks8.7) is a mouse monoclonal IgG1 antibody that detects Cytokeratin 8 in mouse, rat, human, and hamster tissues through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and immunohistochemistry. Cytokeratin 8 is a vital component of the cytoskeletal structure in epithelial cells, playing a crucial role in maintaining cellular integrity and providing mechanical support. Cytokeratin 8 is predominantly located in the cytoplasm of simple epithelial cells, where Cytokeratin 8 forms intermediate filaments that contribute to the overall architecture of the tissue. Cytokeratin 8 expression is particularly significant in epithelial differentiation and tumor characterization, as expression patterns often change in various malignancies. In squamous cell carcinomas derived from stratified epithelia, abnormal Cytokeratin 8 expression can indicate a shift in cellular phenotype associated with malignancy. Cytokeratin 8 expression has been identified as an independent prognostic marker in oral squamous cell carcinomas, correlating with poor patient outcomes. The ability of Cytokeratin 8 to present extracellular epitopes on tumor cells highlights potential therapeutic applications, making anti-Cytokeratin 8 antibody (Ks8.7) an invaluable tool for researchers studying epithelial biology and cancer progression.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Cytokeratin 8 Antibody (Ks8.7) References:

1. Circulating cytokeratin 8:anti-cytokeratin 8 antibody immune complexes in sera of patients with pulmonary fibrosis.  |  Dobashi, N., et al. 2000. Respiration. 67: 397-401. PMID: 10940793
2. Vimentin, cytokeratin 8 and cytokeratin 18 are not specific markers for M-cells in human palatine tonsils.  |  Koshi, R., et al. 2001. J Anat. 199: 663-74. PMID: 11787820
3. Cytokeratin 8 associates with the external leaflet of plasma membranes in tumour cells.  |  Gires, O., et al. 2005. Biochem Biophys Res Commun. 328: 1154-62. PMID: 15707998
4. Cytokeratin 8/18 expression indicates a poor prognosis in squamous cell carcinomas of the oral cavity.  |  Fillies, T., et al. 2006. BMC Cancer. 6: 10. PMID: 16412231
5. Tumor suppressor SMAR1 downregulates Cytokeratin 8 expression by displacing p53 from its cognate site.  |  Pavithra, L., et al. 2009. Int J Biochem Cell Biol. 41: 862-71. PMID: 18822384
6. Cytokeratin 8-MHC class I interactions: a potential novel immune escape phenotype by a lymph node metastatic carcinoma cell line.  |  Wu, MS., et al. 2013. Biochem Biophys Res Commun. 441: 618-23. PMID: 24183726
7. Cytokeratin 8 in venous grafts: a factor of unfavorable long-term prognosis in coronary artery bypass grafting patients.  |  Perek, B., et al. 2013. Cardiol J. 20: 583-91. PMID: 24338534
8. Knockdown of cytokeratin 8 overcomes chemoresistance of chordoma cells by aggravating endoplasmic reticulum stress through PERK/eIF2α arm of unfolded protein response and blocking autophagy.  |  Wang, D., et al. 2019. Cell Death Dis. 10: 887. PMID: 31767864
9. Cytokeratin 8, 18 and 19 in endometrial epithelium of Norplant and norethisterone enanthate injectable progestogen contraceptive users.  |  Wonodirekso, S., et al. 1996. Hum Reprod. 11 Suppl 2: 144-9. PMID: 8982756
10. Cytokeratin 8/18 levels in patients with prostate cancer and benign prostatic hyperplasia.  |  Wolff, JM., et al. 1998. Urol Int. 60: 152-5. PMID: 9644784

The preferred Cytokeratin 8 antibody is Cytokeratin 8 Antibody (C51): sc-8020.